GlassScriptPhysician profile
Jeffrey Young Kim
NPI 1366820409
$5,885.32
in general payments reported to CMS, 2019-2025
30 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.61 · 2021: $306 · 2022: $1,031 · 2023: $1,744 · 2024: $1,500 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $642.07 | 2022-2024 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Takeda Pharmaceuticals U.S.A., INC. | $605.54 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $569.74 | 2021-2025 | Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.26 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $511.80 | 2022-2024 | Zeposia |
| Abbvie INC. | $485.25 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $370.38 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $248.84 | 2022-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $241.70 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $208.63 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $199.19 | 2023-2025 | |
| Ardelyx, INC. | $188.50 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $124.06 | 2021 | |
| Pfizer INC. | $119.73 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $118.27 | 2021-2025 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $114.38 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $84.68 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $81.79 | 2022-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $81.43 | 2023-2025 | Injectafer |
| Madrigal Pharmaceuticals | $64.07 | 2025 | Rezdiffra |
| Lilly USA, LLC | $57.80 | 2023-2025 | Omvoh |
| Pharmacosmos Therapeutics INC. | $36.58 | 2025 | Monoferric |
| Amgen INC. | $28.61 | 2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $27.14 | 2023 | Sutab |
| Cumberland Pharmaceuticals, INC. | $26.90 | 2025 | Kristalose |
| Stryker Corporation | $25.82 | 2025 | Neptune |
| Endogastric Solutions, INC | $25.38 | 2023 | Esophyx |
| Ethicon US, LLC | $23.68 | 2022 | |
| Fresenius Kabi USA, LLC | $17.21 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $16.89 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.